Oncostellae is at the forefront of biopharmaceutical innovation, specializing in the development of small-molecule drugs aimed at addressing significant unmet medical needs in the fields of immunology and oncology. The company has a robust pipeline of proprietary drug candidates, including OST-122, which is designed as a safer, non-systemic JAK inhibitor for the treatment of inflammatory bowel disease (IBD). This drug is notable for its oral administration and localized action within the gastrointestinal tract, which helps to mitigate the severe systemic side effects commonly associated with other JAK inhibitors. The promising results from a Phase 2a clinical trial indicate that OST-122 is well tolerated and may offer a safer therapeutic option for patients suffering from moderate to severe ulcerative colitis.

In addition to OST-122, Oncostellae is advancing other drug candidates such as OST-499, a non-steroidal progesterone receptor antagonist aimed at treating uterine fibroids and related gynecological conditions. The company’s approach combines a strong foundation in medicinal chemistry and pharmacology with a strategic focus on developing clinical candidates through various stages of the drug development process, from discovery to Phase I and II trials. By leveraging a network of collaborators and licensing agreements with established pharmaceutical companies, Oncostellae is positioned to bring innovative therapies to market that address critical health challenges.

Spain

Oncostellae is a biotech startup founded in 2013 by a team of medicinal chemists and pharmacologists. The company focuses on the discovery of new pharmaceutically active compounds and their development, with a particular emphasis on small-molecule drugs with innovative scaffolds that modulate clinically validated therapeutic targets. Oncostellae is a clinical-stage biotech company that is owned by private and institutional investors, and it is involved in the discovery and development of new pharmaceutical compounds.

Cancer

Immune System Diseases

Inflammatory disorders

Oncostellae

Colorectal cancer

Fibrosis

Inflammatory bowel disease

OST-122

Small Molecule Pharmaceuticals

Edificio Feuga, D.5 Rua Lope Gomez De Marzoa, S/N, 15706, Santiago de Compostela, Galicia

Europe - West

Therapeutic

Oncostellae

Company Details